{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Price AM"],"funding":["Centers for Disease Control and Prevention","CDC HHS"],"pagination":["1899-1909"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9006785"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["386(20)"],"pubmed_abstract":["<h4>Background</h4>Spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B.1.1.529 (omicron) variant, which led to increased U.S. hospitalizations for coronavirus disease 2019 (Covid-19), generated concern about immune evasion and the duration of protection from vaccines in children and adolescents.<h4>Methods</h4>Using a case-control, test-negative design, we assessed vaccine effectiveness against laboratory-confirmed Covid-19 leading to hospitalization and against critical Covid-19 (i.e., leading to receipt of life support or to death). From July 1, 2021, to February 17, 2022, we enrolled case patients with Covid-19 and controls without Covid-19 at 31 hospitals in 23 states. We estimated vaccine effectiveness by comparing the odds of antecedent full vaccination (two "],"journal":["The New England journal of medicine"],"pubmed_title":["BNT162b2 Protection against the Omicron Variant in Children and Adolescents."],"pmcid":["PMC9006785"],"funding_grant_id":["75D30121C10297"],"pubmed_authors":["Nofziger RA","Patterson K","Kelley CP","Moran P","Zambrano LD","Malloch L","Bline KE","Glas Gaspers M","Johnston MS","Martin L","Maamari M","Gertz SJ","Khan HA","Oates JN","Rohlfs CC","Schwartz SP","Orzel AO","He J","Twinem NA","Maddux AB","Heidemann SM","Douglas RL","Chiotos K","Smallcomb L","Price AM","Bradford TT","Carson I","Sanders C","Murdock M","Bline K","Behl S","Randolph AG","Weller E","Cullimore ML","Mack EH","Rowan CM","Peralta H","Tenforde MW","Port E","Hume JR","Hakimi D","Levy ER","Patel MM","Wolfe A","Campbell AP","McCadden TP","Kong M","Hill SM","Overcoming Covid-19 Investigators","Murcia-Montoya J","Drapeau NM","Bickford MM","Sahni LC","Walker TC","Flori HR","Kucukak S","Wakefield LE","Boutselis BJ","Tomcany ML","Boom JA","Crane K","Phengchomphet K","Halasa NB","Baida N","Yates M","Skura AL","Irby K","Sanders RC","Mrotek KG","Typpo KV","Villarreal-Chico D","Bhumbra SS","Bowens C","Hobbs CV","Lionetti G","Stewart LS","Cvijanovich NZ","Chen SR","Mack H","Harrison VA","Golchha M","Rinehart VH","Sullivan M","Staat MA","Zinter MS","Michelson KN","Olson SM","Newhams MM","Kamidani S","Stumpf M","Schuster JE","Pannaraj PS","Hussaini L","Coates BM","Lockwood JM","Berbert L","Smith C","Chatani BM","Cameron MA","Rhodes ST","Tarquinio KM","Hoody LA","Bruno ER","Sea YJ","Goertzen LA","Bennett PC"],"additional_accession":[]},"is_claimable":false,"name":"BNT162b2 Protection against the Omicron Variant in Children and Adolescents.","description":"<h4>Background</h4>Spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B.1.1.529 (omicron) variant, which led to increased U.S. hospitalizations for coronavirus disease 2019 (Covid-19), generated concern about immune evasion and the duration of protection from vaccines in children and adolescents.<h4>Methods</h4>Using a case-control, test-negative design, we assessed vaccine effectiveness against laboratory-confirmed Covid-19 leading to hospitalization and against critical Covid-19 (i.e., leading to receipt of life support or to death). From July 1, 2021, to February 17, 2022, we enrolled case patients with Covid-19 and controls without Covid-19 at 31 hospitals in 23 states. We estimated vaccine effectiveness by comparing the odds of antecedent full vaccination (two ","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 May","modification":"2025-04-25T18:01:45.804Z","creation":"2025-04-25T18:01:45.804Z"},"accession":"S-EPMC9006785","cross_references":{"pubmed":["35353976"],"doi":["10.1056/NEJMoa2202826"]}}